Korea FDA Evaluating H1N1 Vaccine Applications from GSK and Three Korean Pharmas
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Korea FDA said it is evaluating three applications for the A/H1N1 flu vaccine submitted by GlaxoSmithKline and Korean companies Green Cross, Boryung Pharmaceutical and Hanwha Pharma
You may also be interested in...
President Obama's Declaration Of National Emergency Triggers H1N1 Jitters Halfway Around The World In Korea
SEOUL - As government leaders mull whether to temporarily close down all schools across South Korea, and amid jitters caused by the declaration of a national emergency in the U.S. by President Barack Obama, the Korea Food & Drug Administration has given the green light to Korean biotech outfit Green Cross to use its new vaccine in the country's inoculation drive against A/H1N1
President Obama's Declaration Of National Emergency Triggers H1N1 Jitters Halfway Around The World In Korea
SEOUL - As government leaders mull whether to temporarily close down all schools across South Korea, and amid jitters caused by the declaration of a national emergency in the U.S. by President Barack Obama, the Korea Food & Drug Administration has given the green light to Korean biotech outfit Green Cross to use its new vaccine in the country's inoculation drive against A/H1N1
String Of Deaths In Korea Among Inoculated Elderly Not Caused By Vaccines Produced By GSK, Novartis
SEOUL - Officials at the Korea Centers for Disease Control and Prevention say that the recent deaths of five elderly citizens who had been inoculated with seasonal flu vaccines were not caused by bulk vaccine products supplied by GSK and Novartis